REGENXBIO Inc. (FRA:RB0)
Germany · Delayed Price · Currency is EUR 7.10
+0.45 (6.77%)
At close: Feb 20, 2026
REGENXBIO Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 161.32 | 83.33 | 90.24 | 112.72 | 470.35 | 154.57 |
Revenue | 161.32 | 83.33 | 90.24 | 112.72 | 470.35 | 154.57 |
Revenue Growth (YoY) | 91.30% | -7.66% | -19.94% | -76.03% | 204.30% | 338.70% |
Cost of Revenue | 239.76 | 242.09 | 266.48 | 297 | 233.27 | 202.01 |
Gross Profit | -78.44 | -158.76 | -176.24 | -184.27 | 237.08 | -47.44 |
Selling, General & Admin | 80.53 | 76.62 | 87.79 | 85.28 | 79.33 | 63.82 |
Other Operating Expenses | 0.96 | 0.87 | 0.4 | -14.18 | 0.33 | 0.3 |
Operating Expenses | 76.49 | 72.48 | 88.19 | 71.1 | 77.1 | 71.79 |
Operating Income | -154.93 | -231.25 | -264.43 | -255.38 | 159.98 | -119.23 |
Interest Expense | -42.15 | -12.66 | -6.86 | -23.25 | -26.28 | -0.77 |
Interest & Investment Income | 19.16 | 18.9 | 11.34 | 5.73 | 7.54 | 13.99 |
EBT Excluding Unusual Items | -177.92 | -225 | -259.95 | -272.91 | 141.25 | -106.01 |
Merger & Restructuring Charges | - | - | -3.7 | - | - | - |
Asset Writedown | - | -2.1 | - | - | - | - |
Other Unusual Items | - | - | - | -7.5 | - | - |
Pretax Income | -177.92 | -227.1 | -263.65 | -280.41 | 141.25 | -106.01 |
Income Tax Expense | - | - | -0.15 | -0.08 | 13.41 | 5.24 |
Net Income | -177.92 | -227.1 | -263.49 | -280.32 | 127.84 | -111.25 |
Net Income to Common | -177.92 | -227.1 | -263.49 | -280.32 | 127.84 | -111.25 |
Shares Outstanding (Basic) | 51 | 50 | 44 | 43 | 42 | 37 |
Shares Outstanding (Diluted) | 51 | 50 | 44 | 43 | 44 | 37 |
Shares Change (YoY) | 7.46% | 13.21% | 1.35% | -1.73% | 17.79% | 1.61% |
EPS (Basic) | -3.46 | -4.59 | -6.02 | -6.50 | 3.01 | -2.98 |
EPS (Diluted) | -3.46 | -4.59 | -6.02 | -6.50 | 2.91 | -2.98 |
Free Cash Flow | -106.28 | -175.56 | -228.37 | -238.21 | 134.7 | -80.93 |
Free Cash Flow Per Share | -2.07 | -3.55 | -5.22 | -5.52 | 3.07 | -2.17 |
Gross Margin | -48.62% | -190.53% | -195.29% | -163.47% | 50.41% | -30.69% |
Operating Margin | -96.04% | -277.51% | -293.02% | -226.55% | 34.01% | -77.14% |
Profit Margin | -110.29% | -272.54% | -291.99% | -248.68% | 27.18% | -71.97% |
Free Cash Flow Margin | -65.88% | -210.69% | -253.06% | -211.32% | 28.64% | -52.36% |
EBITDA | -139.16 | -215.03 | -247.11 | -242.47 | 169.54 | -110.83 |
EBITDA Margin | -86.27% | -258.05% | -273.83% | -215.10% | 36.05% | -71.70% |
D&A For EBITDA | 15.77 | 16.22 | 17.32 | 12.91 | 9.56 | 8.41 |
EBIT | -154.93 | -231.25 | -264.43 | -255.38 | 159.98 | -119.23 |
EBIT Margin | -96.04% | -277.51% | -293.02% | -226.55% | 34.01% | -77.14% |
Effective Tax Rate | - | - | - | - | 9.49% | - |
Revenue as Reported | 161.32 | 83.33 | 90.24 | 112.72 | 470.35 | 154.57 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.